59 related articles for article (PubMed ID: 35015315)
1. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis.
Abuhelwa Z; Beran A; Kahlon N; Sayeh W; Khokher W; Assaly R; Hamouda DM
Am J Ther; 2023 Nov-Dec 01; 30(6):e573-e575. PubMed ID: 35446286
[No Abstract] [Full Text] [Related]
3. Is lirentelimab the 'magic bullet' to fight pathological mast-cell activation in systemic mastocytosis?
Barete S; Arock M
Br J Dermatol; 2023 Oct; 189(5):503-504. PubMed ID: 37403635
[No Abstract] [Full Text] [Related]
4. Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report.
Zhou M; Zhong G; Yu Y; Wang R; Ma S; Chen C
Ann Hematol; 2023 Oct; 102(10):2951-2953. PubMed ID: 37432413
[No Abstract] [Full Text] [Related]
5. A study of the safety and effectiveness of lirentelimab as a treatment for people with indolent systemic mastocytosis.
Br J Dermatol; 2023 Oct; 189(5):e88. PubMed ID: 37879742
[No Abstract] [Full Text] [Related]
6. A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin.
Sciumè M; Serpenti F; Muratori S; Pravettoni V; Ulivieri FM; Croci GA; Migliorini AC; Esposito A; Goldaniga MC; Saporiti GN; Galassi G; Baldini L; Onida F; Grifoni FI
Clin Case Rep; 2021 Feb; 9(2):978-982. PubMed ID: 33598282
[TBL] [Abstract][Full Text] [Related]
7. Target Therapies for Systemic Mastocytosis: An Update.
Sciumè M; De Magistris C; Galli N; Ferretti E; Milesi G; De Roberto P; Fabris S; Grifoni FI
Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745657
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
9. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience.
Farrukh F; Gangat N; Shah MV; Litzow MR; Elliott MA; Begna K; Hook CC; Tefferi A; Pardanani A
Am J Hematol; 2022 Apr; 97(4):E138-E140. PubMed ID: 35015315
[No Abstract] [Full Text] [Related]
11. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.
van Anrooij B; Oude Elberink JNG; Span LFR; de Monchy JGR; Rosati S; Mulder AB; Kluin-Nelemans JC
J Allergy Clin Immunol; 2018 Sep; 142(3):1006-1008.e7. PubMed ID: 29890238
[No Abstract] [Full Text] [Related]
13. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
